Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- After Delay, CSIMC Recommends Listing of Ilaris for Treatment of CAPS
November 21, 2011
- US FDA Revokes Avastin’s Approval for Metastatic Breast Cancer
November 21, 2011
- Former Chuikyo Chairman Prof. Endo Concerned about Increasing Drug Expenditure
November 21, 2011
- CSIMC Subcommittee Approves Special Price Reductions for Combination Drugs
November 18, 2011
- CSIMC Excludes DPC Flat-Sum Reimbursement, Recommends Approval for Reimbursement by Piecework for 5 APIs
November 18, 2011
- Korosho Approves 3 Switch OTC Products Containing Pemirolast
November 18, 2011
- Similar Products to Be Re-Priced by Product Following Market Expansion: CSIMC Expert Subcommittee
November 17, 2011
- Industry Renews Call for Perpetual Introduction of Premium for New Drug Development: CSIMC Expert Subcommittee
November 17, 2011
- Re-pricing of Essential Drugs Discussed at CSIMC
November 17, 2011
- CSIMC Recommends Listing of 9 Products Including Imusera; Recommendation Put on Hold for Ilaris
November 17, 2011
- Plaintiffs to Appeal Against “Unprecedented Unjust Ruling”: Iressa Appeal Trial
November 17, 2011
- Subcommittee to Study “Notification System” for Access to Unapproved Drugs
November 17, 2011
- PM Noda Says “Japan Will Not Lose” Public Health Insurance System in TPP
November 16, 2011
- Health Minister Komiyama Says “Government Position Recognized” in Iressa Case
November 16, 2011
- DPJ’s Medical and Nursing Care WT Discuss Promotion of Generic Drugs
November 16, 2011
- High Court Turns Down Iressa Compensation Appeal
November 16, 2011
- 7-Drug Rule Should Be Relaxed or Eliminated to Promote GE Name Prescribing: Dr Adachi of CSIMC
November 16, 2011
- Mr Sawai of JGA Opposes Reduction in NHI Prices of First Generics
November 16, 2011
- PAFSC Committee Recommends Classification of Isoconazole as Class 1 OTC Drug
November 15, 2011
- Merck Withdraws MAA for Sitagliptin, Pioglitazone Combination
November 15, 2011
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…